Suchergebnisse - "Kada, Akiko"

PubPharm (171)

1

Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021)

enthalten in: International journal of hematology | 2024

von Shibayama, H. | Itagaki, M. | Handa, H. | +27

2

Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma : A report from the JPLSG B-NHL14 trial

enthalten in: European journal of haematology | 2024

von Mori, T. | Osumi, T. | Kada, A. | +10

3

Talc slurry pleurodesis in patients with secondary intractable pneumothorax : A phase 2 study

enthalten in: Respiratory investigation | 2024

von Saka, H. | Oki, M. | Yamauchi, Y. | +9

4

Rituximab with standard LMB chemotherapy in pediatric high‐risk mature B‐cell non‐Hodgkin lymphoma : A report from the JPLSG B‐NHL14 trial

enthalten in: European Journal of Haematology | 2024

von Mori, T. | Osumi, T. | Kada, A. | +10

5

Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11) : a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group

enthalten in: The Lancet. Haematology | 2023

von Sato, A. | Hatta, Y. | Imai, C. | +23

CommentIn: Lancet Haematol. 2023 Jun;10(6):e391-e393. - PMID 37167993

6

National trends in the outcomes of subarachnoid haemorrhage and the prognostic influence of stroke centre capability in Japan : retrospective cohort study

enthalten in: BMJ open | 2023

von Kurogi, R. | Kada, A. | Ogasawara, K. | +137

7

Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC : Post Hoc Analysis of the CAPITAL Study

enthalten in: JTO clinical and research reports | 2023

von Kogure, Y. | Kada, A. | Hashimoto, H. | +14

8

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

enthalten in: BMC cancer | 2022

von Fukui, T. | Sasaki, J. | Igawa, S. | +5

9

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

enthalten in: BMC cancer | 2022

von Fukui, T. | Sasaki, J. | Igawa, S. | +5

10

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

enthalten in: BMC cancer | 2022

von Fukui, T. | Sasaki, J. | Igawa, S. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]